血浆源性与重组凝血因子VIII免疫原性的生物学考量
在A型血友病中,25%至30%的患者接受凝血因子VIII替代治疗后会产生中和抗体(抑制剂),这是最严重的并发症。抑制剂发生受遗传因素(如FVIII基因型)与环境变量(如合并炎症)的复杂平衡调控,凝血因子VIII浓缩物来源(重组或血浆源性)是假设的风险因素之一。近期多项流行病学研究记录了这些浓缩物免疫原性的差异,但生物学机制解释尚不清楚,本文概述了可能贡献于血浆源性与重组FVIII产品不同免疫结局的生化与免疫学机制。
要点
- A型血友病患者中25%至30%接受FVIII替代治疗者会产生FVIII中和抗体(抑制剂)。
- 抑制剂发生受遗传因素(如FVIII基因型)与环境变量(如合并炎症)的复杂平衡调控。
- 凝血因子VIII浓缩物来源(重组或血浆源性)是抑制剂发生的假设风险因素之一。
核心结论
- 本文在现有流行病学调查基础上,概述了可能贡献于血浆源性与重组FVIII产品不同免疫结局的生化与免疫学机制。
研究设计与样本
- 本文为综述,补充现有流行病学调查,概述可能的生化与免疫学机制。
主要发现
- FVIII抑制剂在25%至30%的接受替代治疗患者中形成。
- 抑制剂发生受遗传因素(如FVIII基因型)与环境变量(如合并炎症)的复杂平衡调控。
- 近期多项流行病学研究记录了血浆源性与重组FVIII浓缩物免疫原性的差异。
局限性
- 目前讨论未能就如何将这些结局整合到改善临床护理中达成共识。
- 对观察到的差异的生物学机制解释知之甚少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In hemophilia A, the most severe complication of factor VIII (FVIII) replacement therapy involves the formation of FVIII neutralizing antibodies, also known as inhibitors, in 25% to 30% of patients. This adverse event is associated with a significant increase in morbidity and economic burden, thus highlighting the need to identify methods to limit FVIII immunogenicity. Inhibitor development is regulated by a complex balance of genetic factors, such as FVIII genotype, and environmental variables, such as coexistent inflammation. One of the hypothesized risk factors of inhibitor development is the source of the FVIII concentrate, which could be either recombinant or plasma derived. Differential immunogenicity of these concentrates has been documented in several recent epidemiologic studies, thus generating significant debate within the hemophilia treatment community. To date, these discussions have been unable to reach a consensus regarding how these outcomes might be integrated into enhancing clinical care. Moreover, the biological mechanistic explanations for the observed differences are poorly understood. In this article, we complement the existing epidemiologic investigations with an overview of the range of possible biochemical and immunologic mechanisms that may contribute to the different immune outcomes observed with plasma-derived and recombinant FVIII products.
引用
- Lai J, Hough C, Tarrant J, et al. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. 2017. PMID: 28432221. doi:10.1182/blood-2016-11-750885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。